Visa Inc. – Consensus Indicates Potential 30.2% Upside

DirectorsTalk Interviews

Visa Inc. with ticker code (V) now have 37 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 296 and 220 calculating the average target price we see 261.34. Given that the stocks previous close was at 200.71 this is indicating there is a potential upside of 30.2%. The 50 day moving average now sits at 207.77 and the 200 day moving average is 210.2. The company has a market capitalisation of $422,979m. Find out more information at: https://usa.visa.com

The potential market cap would be $550,751m based on the market concensus.

Visa Inc. operates as a payments technology company worldwide. The company facilitates digital payments among consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It operates VisaNet, a transaction processing network that enables authorization, clearing, and settlement of payment transactions. In addition, the company offers card products, platforms, and value-added services. It provides its services under the Visa, Visa Electron, Interlink, VPAY, and PLUS brands. Visa Inc. has a strategic agreement with Ooredoo to provide an enhanced payment experience for Visa cardholders and Ooredoo customers in Qatar. Visa Inc. was founded in 1958 and is headquartered in San Francisco, California.

Share on:

Latest Company News

Domino’s Pizza Group delivers solid FY2025 finish, maintains outlook for 2026

Domino’s Pizza Group posted modest sales growth in FY2025 and strong cash generation, supporting a higher dividend. The company said trading in early 2026 remains in line with market expectations as it focuses on core growth, digital expansion, and operational efficiency.

Grafton Group agrees deal to acquire Cygnum in Ireland

Grafton Group has agreed to acquire Irish offsite timber frame supplier Cygnum Holdings, strengthening Chadwicks Group’s offering and expanding its exposure to Ireland’s growing modular housing market.

ICG appoints Jonathon Bond as Independent Non-Executive Director

Jonathon Bond will join the ICG Board on 1 April 2026 and serve on the Remuneration Committee, as Stephen Welton and Rosemary Leith announce plans to retire at the July 2026 AGM.

Spirax Group reports 2025 results with 5% organic revenue growth and margin progress

Spirax Group reported 2025 revenue of £1.7bn, up 5% organically and ahead of global industrial production. Adjusted operating profit rose 6%, while statutory profit declined due to restructuring costs.

Persimmon posts 2025 growth as sales and revenue rise

Persimmon increased completions, revenue and profits in 2025, with housing revenue up 16% to £3.31bn. The company expects 12,000–12,500 completions in 2026, supported by strong forward sales and improved market conditions.

Nuformix receives FDA Orphan Drug status for NXP002 IPF programme

The FDA has granted Orphan Drug Designation to tranilast lystate, the active compound in Nuformix’s NXP002 programme targeting idiopathic pulmonary fibrosis, a rare lung disease affecting fewer than 200,000 people in the United States.

    Search